Alexandria, VA— May 29, 2020 — Gunnison is proud to work with the Food and
Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER),
Office of Business Informatics (OBI) to implement solutions for the current
COVID-19 crisis. Our team recently provided quality assurance and
end-to-end analysis and testing support for the Alternate Submissions
System that expedites the application process for COVID-19 treatment
submissions and the COVID-19 Critical Care Drug Monitoring Survey Portal
for use by hospitals and organizations to submit frequent drug demand
surveys for COVID-19. Several teams and contractors worked with FDA
leadership to expedite the development timeline for these systems that will
accelerate discovery of treatments for COVID-19 in the coming months.
Gunnison has provided quality assurance, business analysis, and end-to-end
testing support at FDA for the past 4 years as they modernize their
processes and systems to meet the challenges of ensuring safe and effective
drugs and treatments are made available to the public in a timely manner.
About Gunnison
Founded in 1994, Gunnison is celebrating 25 years as a certified small
business. Gunnison takes pride in tackling its clients’ most ambitious IT
projects and serving its critical mission objectives. Other major customers
include the U.S. Patent and Trademark Office and the Census Bureau.